Simplify Asset Management Inc. Sells 16,006 Shares of Celldex Therapeutics, Inc. $CLDX

Simplify Asset Management Inc. reduced its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 18.8% during the 1st quarter, Holdings Channel.com reports. The fund owned 68,994 shares of the biopharmaceutical company’s stock after selling 16,006 shares during the period. Simplify Asset Management Inc.’s holdings in Celldex Therapeutics were worth $2,188,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB acquired a new stake in Celldex Therapeutics in the 3rd quarter valued at $42,000. Russell Investments Group Ltd. raised its stake in Celldex Therapeutics by 27.6% during the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 501 shares in the last quarter. Quantbot Technologies LP acquired a new position in Celldex Therapeutics during the third quarter worth $63,000. Kestra Advisory Services LLC bought a new position in shares of Celldex Therapeutics during the fourth quarter valued at $98,000. Finally, Headlands Technologies LLC bought a new position in shares of Celldex Therapeutics during the second quarter valued at $125,000.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on CLDX. UBS Group raised their price objective on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. HC Wainwright reissued a “buy” rating and issued a $42.00 target price on shares of Celldex Therapeutics in a report on Monday, June 15th. Wall Street Zen upgraded Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Wells Fargo & Company lifted their price objective on Celldex Therapeutics from $38.00 to $54.00 and gave the company an “overweight” rating in a research report on Wednesday, May 13th. Finally, Wolfe Research upgraded Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 target price on the stock in a report on Monday, March 23rd. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Celldex Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $49.30.

Celldex Therapeutics Price Performance

NASDAQ:CLDX opened at $38.37 on Friday. Celldex Therapeutics, Inc. has a 12-month low of $19.72 and a 12-month high of $39.16. The stock’s fifty day simple moving average is $32.40 and its 200-day simple moving average is $29.56. The firm has a market capitalization of $3.01 billion, a P/E ratio of -9.01 and a beta of 0.90.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.80 million. As a group, equities research analysts expect that Celldex Therapeutics, Inc. will post -4.36 earnings per share for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.